AAX Biotech's Technology to be Utilized in BioArctic’s Research Project
Biotech company AAX Biotech, specializing in innovative technologies for improving antibody-based medicines, is excited to announce that BioArctic AB, a renowned Swedish biopharma company focused on neurodegenerative diseases, has decided to utilize AAX Biotech's proprietary epitope mapping technology, Seqitope™.
AAX Biotech is dedicated to addressing unmet demands in the advancement of next-generation antibody therapeutics. The company’s two pioneering technologies, Seqitope™ and Opti-mAb™, improve the performance and developability of antibody-based therapeutics and offer a unique solution in a rapidly growing market.
This marks a significant milestone for AAX Biotech, highlighting the company's role in advancing research with its Seqitope™ technology—a high-resolution, high-throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics.
"Having BioArctic use our technology represents a unique opportunity for AAX Biotech to contribute to the fight against neurodegenerative diseases which affect millions of persons worldwide," says Maria L. Knudsen, CEO of AAX Biotech. "We are fully committed to this challenging project and are eager to apply our technology to support BioArctic."
For more information, please contact:
Maria Lisa Knudsen, CEO
+46 72 939 5018
maria.knudsen@aaxbiotech.com
About AAX Biotech AB
AAX Biotech AB is a biotech company specializing in next-generation antibody therapeutics. The company offers two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high throughput and high-resolution epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Both technologies aim to produce better and more effective antibody-based medicines. These innovations position AAX Biotech as a key player in the rapidly growing antibody therapeutics market. AAX Biotech is founded by experts from Karolinska Institutet in Stockholm, Sweden. Visit aaxbiotech.com to learn more and follow AAX Biotech on LinkedIn.
Tags:
